Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 17/20 | 0.76 |
| ▸ | KCNK9 | Q9NPC2 | 17/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18952321 | 0.88 | KCNK3 (0.93) | KCNK3KCNK9 | |
| SCHEMBL18963165 | 0.87 | KCNK3 (1.00) | KCNK3KCNK9SLC2A1 | |
| SCHEMBL25423903 | 0.86 | KCNK3 (0.76) | KCNK3KCNK9 | |
| SCHEMBL18963135 | 0.86 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL18963162 | 0.86 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL18952242 | 0.86 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL18952325 | 0.85 | KCNK3 (1.00) | KCNK3KCNK9KDM4E | |
| SCHEMBL18963196 | 0.85 | KCNK3 (0.79) | KCNK3KCNK9 | |
| SCHEMBL18963203 | 0.85 | KCNK3 (1.00) | KCNK3KCNK9SLC2A1 | |
| SCHEMBL18963158 | 0.85 | KCNK3 (1.00) | KCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759794-B2 | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759794-B2 | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders | TRPV2, CACNA1G, KCNJ2 | KCNK3 85/4885KCNK9 204/4885KDM4E 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.